Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer

Abstract

BackgroundClass III β-tubulin, Sox2, and Survivin play important roles in tumor survival and proliferation. However, the association of these three factors with clinicopathological characteristics, chemoresistance, and survival in patients with ovarian cancer remains controversial.MethodsWe investigated the predictive value and correlation among the expression levels of Class III β-tubulin, Sox2, and Survivin in 110 patients with stage III ovarian epithelial cancer, including 58 patients who received taxane-based chemotherapy and 52 patients who received non-taxane-based chemotherapy. Expression of these three factors was immunohistochemically examined in 110 ovarian tumor tissues obtained from patients before chemotherapy.ResultsThe positive expression rates for Class III β-tubulin, Sox2, and Survivin in ovarian tumor tissues were 59.09 %, 61.82 % and 52.73 %, respectively. The expression of nuclear Survivin and Class III β-tubulin was consistent with that of Sox2 (p = 0.005 and 0.020, respectively). Positive expression of Class III β-tubulin, Sox2, and nuclear Survivin was significantly associated with chemoresistance to taxane-based chemotherapy (p = 0.006, 0.007, and 0.009, respectively), but not to non-taxane-based chemotherapy. Additionally, overexpression of Class III β-tubulin, Sox2, and nuclear Survivin predicted poor progression-free survival in patients receiving taxane-based chemotherapy (p = 0.032, 0.005, and 0.004, respectively).ConclusionsThese findings suggest that overexpression of Class III β-tubulin, Sox2, and nuclear Survivin might be predictive of taxane resistance and poor progression-free survival in patients with stage III ovarian epithelial cancer. Expression of these three factors may show positive correlations in these patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1553-x) contains supplementary material, which is available to authorized users.

The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer

“…As for invasion assay, we found that knockdown of survivin protein inhibited the invasive abilities of BGC823 cells into Matrigel compared with control. Consistent with our findings, recent articles also reported the silencing of survivin also affected the capacity of migration and invasion of a variety of cancers, such as breast cancer [13] and liver cancer [18].…”

“…Each bar represents the mean ±SEM of three independent experiments; *p<0.001, compared with control, using oneway ANOVA followed by the Dunnett's t test multiple comparisons test for between-group analysis some key events in the signaling pathways of tumors [12]. At the same time, survivin has been reported to be involved in the progression of cancers [13]. However, IGF1-survivin pathway was scarcely demonstrated and the associations with EMT were not reported.…”

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy

“…Furthermore, many investigators have paid attention to the relationships between TUBB3 expression and efficacy of a variety of chemotherapeutic agents in patients with advanced stage malignancies. For example, in vivo and in vitro studies demonstrated that TUBB3 expression was associated with chemoresistance to taxanes in ovarian, breast, and lung cancer (8)(9)(10). In addition to its relationship with taxanes, several investigators reported that TUBB3 affected the response to DNAdamaging agents, including platinum-based agents, in lung cancer (11,12).…”

Synthesis and biological evaluation of quinoxaline derivatives as tubulin polymerization inhibitors that elevate intracellular ROS and triggers apoptosis via mitochondrial pathway

“…Currently, all the United States Food and Drug Administration (FDA) approved MDAs for cancer therapy target either taxanes (e.g., paclitaxel, docetaxel) or vinca alkaloids (e.g., vinblastine, vincristine). However, the clinical efficacy of the drugs is often limited by occurrence and evolution of resistance mechanisms that is further compounded by a narrow therapeutic index (Du et al., ; Gigant et al., ; Kavallaris, ; Perez, ; Wang, Chen, Miller, & Li, ; Wang et al., ). Recently, some colchicine binding tubulin inhibitors exhibit significant ability to overcome multidrug resistance (Bacher et al., ; Banerjee et al., ; Bueno et al., ; Cui et al., ; Dohle et al., ; Gangjee et al., ; Lauria et al., ; Li et al., ; Ohsumi et al., ; Pang et al., ; Suman et al., ).…”